Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SENL-002 by Hebei Senlang Biotechnology for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
SENL-002 is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...